Tufts Study: Cancer Drugs Now Account for 27% of all New Drug Approvals

September 5, 2019

Applied Clinical Trials

A newly completed analysis from the Tufts Center for the Study of Drug Development shows that from 1980 through 2018, the FDA approved a total of 126 cancer drugs to treat solid and hematologic tumors. A dramatic increase to 27% from the 4% share of the 1980s.

For more findings, click here.

Related Content:

News